Certara Inc. (CERT): Price and Financial Metrics
CERT Price/Volume Stats
| Current price | $16.16 | 52-week high | $24.70 |
| Prev. close | $15.93 | 52-week low | $11.81 |
| Day low | $15.78 | Volume | 568,200 |
| Day high | $16.40 | Avg. volume | 540,275 |
| 50-day MA | $17.77 | Dividend yield | N/A |
| 200-day MA | $16.30 | Market Cap | 2.59B |
CERT Stock Price Chart Interactive Chart >
Certara Inc. (CERT) Company Bio
Certara, Inc. engages in the provision of software and technology enables services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017 and is headquartered in Princeton, NJ.
Latest CERT News From Around the Web
Below are the latest news stories about CERTARA INC that investors may wish to consider to help them evaluate CERT as an investment opportunity.
Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel TherapiesCombined organization establishes the life sciences industry’s largest quantitative systems pharmacology (QSP) center of excellence contributing to faster and more effective medicine development.PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) today announced it has acquired Applied BioMath, an industry-leader in providing model-informed drug discovery and development support to help accelerate and de-risk therapeutic research and development (R&D). Together, Certa |
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & developmentSimcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapiesPRINCETON, N.J., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the introduction of Simcyp™ Biopharmaceutics software. It is designed for use by biopharmaceutic, formulation, and CMC scientists to aid in formulating complex novel and generic small molecule medicines quickly and cost effective |
Certara, Inc. (NASDAQ:CERT) Q3 2023 Earnings Call TranscriptCertara, Inc. (NASDAQ:CERT) Q3 2023 Earnings Call Transcript November 8, 2023 Certara, Inc. reports earnings inline with expectations. Reported EPS is $0.11 EPS, expectations were $0.11. Operator: Good day, and thank you for standing by. Welcome to the Certara Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being […] |
Q3 2023 Certara Inc Earnings CallQ3 2023 Certara Inc Earnings Call |
Certara, Inc. (CERT) Q3 Earnings Meet EstimatesCertara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 0.45%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
CERT Price Returns
| 1-mo | -6.86% |
| 3-mo | 0.37% |
| 6-mo | 29.70% |
| 1-year | -33.58% |
| 3-year | -48.06% |
| 5-year | N/A |
| YTD | -8.13% |
| 2023 | 9.46% |
| 2022 | -43.46% |
| 2021 | -15.72% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...